Photocoagulation treatment for clinically significant radiation macular oedema

James L Kinyoun, Ronald W Zamber, Betty S Lawrence, William E Barlow, Alice M Arnold

Abstract

Macular oedema is a leading cause of vision loss in patients with radiation retinopathy. In an effort to find an effective treatment for this vision threatening complication, 12 eyes (eight patients) were treated with photocoagulation for clinically significant radiation macular oedema (CSRMO) defined as central macular thickening, exudates threatening the macular centre, or one disc area of thickening in the macula. Median visual acuity improved from 20/100 preoperatively to 20/90 at the initial postoperative examination (mean follow up 5 months) and to 20/75 at the final postoperative examination (mean follow up 39 months). At the final postoperative examination, visual acuity had improved in eight (67%) eyes and six (50%) eyes had complete resolution of the CSRMO; two (17%) other eyes had improved anatomically in that fewer CSRMO criteria were present. These results suggest that macular photocoagulation is effective in decreasing macular oedema and improving vision in eyes with CSRMO. (Br J Ophthalmol 1995; 79: 144-149)

Patients and methods

Eight patients, four with bilateral involvement or a total of 12 eyes, were enrolled and gave informed consent for macular photocoagulation treatment. To be eligible, affected patients had to have a history of radiation treatment around the eyes or head as well as clinical findings consistent with radiation retinopathy (microaneurysms, telangiectasia, and/or nerve fibre layer infarcts) plus radiation macular oedema with one or more criteria for being clinically significant as defined by the Early Treatment Diabetic Retinopathy Study Research Group. These criteria include:

1. (centre) retinal thickening at or within 500 µm of the centre of the macula;
2. (exudates) hard exudates within 500 µm of the centre of the macula, if associated with adjacent retinal thickening; or
3. (zone) a zone or zones of retinal thickening one disc area or larger, any part of which is within one disc diameter of the centre of the macula.

Eyes with macular oedema which was not clinically significant (retinal thickening or appreciable hard exudates within one disc diameter of the centre of the macula) were not eligible for treatment. None of our patients’ retinopathy was suggestive of a branch vein occlusion (sectoral distribution) or central retinal vein occlusion (venous dilatation). One patient had adult onset diabetes mellitus but the retinopathy did not occur until 11 months after radioactive plaque treatment, and this patient’s opposite macula was normal. Examination techniques used to detect radiation retinopathy, macular oedema, and CSRMO included ophthalmoscopy (direct and indirect), contact lens fundus biomicroscopy, and stereoscopic colour fundus photographs.

Snellen visual acuity was measured and recorded by independent examiners at the preoperative and postoperative examinations. For eyes with visual acuity less than 20/400, acuity was recorded as counting fingers or hand movements. For visual acuity analyses, counting fingers and hand movements were arbitrarily converted to 20/800 and 20/1600, respectively. Preoperative stereoscopic colour fundus photographs and fluorescein angiograms were obtained for all 12 study eyes. CSRMO criteria were recorded for the preoperative examination, the postoperative examination occurring closest to 4 months following treatment (referred to as initial
Photocoagulation for clinically significant 20/100. Each recorded visual acuity with initial and final pre- and postoperatively. (CF= counting fingers; HM= hand movements.)

Results
Five men and three women were enrolled. Seven right eyes and five left eyes met the inclusion criteria for macular photocoagulation treatment. The four eyes in these patients which were not treated included two normal eyes of two patients with unilateral intraocular tumour, one eye with a markedly atrophic nerve and macula due to radiation damage, and one eye with very early radiation retinopathy (only occasional retinal haemorrhages and microaneurysms). The mean age of these patients at the time of radiation treatment was 35 years with a range of 6 months to 62 years. The mean age at the first treatment for CSRMO was 44 years with a range of 17 to 70 years. The indications for radiation treatment included three patients (five eyes) with Graves' ophthalmopathy, eight patients (five eyes) with central nervous system tumour, and two patients (two eyes) with intraocular tumour. Eleven eyes were treated with external beam irradiation and one eye had local radioactive plaque treatment of a peripheral choroidal melanoma. Mean fraction size was 276 rad based on a mean total of 4971 rad given over a mean total of 18 fractions (ranges of 2000 to 10 710 rad and 1 to 33 fractions). The mean (median) latencies for the first diagnosis of radiation retinopathy, macular oedema, and CSRMO were 55 (27), 70 (34), and 87 (63) months, respectively. The range for each of these three diagnoses was 11–273, 11–273, and 11–329 months, respectively.

At the time of macular photocoagulation, all 12 eyes had thickening involving the centre of the macula, seven eyes had hard exudates associated with thickening, and 10 eyes had a disc area of thickening. The median preoperative visual acuity for these 12 eyes was 20/100 with a range of 20/40 to counting fingers. At the initial postoperative examination (mean of 5 months with range of 3–8 months after treatment), the median visual acuity was 20/90 with a range of 20/20 to counting fingers. The mean total follow up for these 12 eyes was 39 (range 6–76) months. Median visual acuity at the final postoperative examination was 20/75 with a range of 20/20 to hand motion.

During follow up, these 12 eyes had an average of one retreatment for persistent or recurrent clinical significant macular oedema. The total number of retreatments ranged from 0 to 4; eight eyes had one or no retreatment. Additional macular photocoagulation was recommended for two patients (two eyes) at the final postoperative examination.

We found that a majority of eyes (seven and eight) had better visual acuity at both the initial and final postoperative examinations, respectively (Fig 1). Four eyes had at least halving of the visual angle at the initial postoperative examination and seven eyes had improved this amount at the final postoperative examination. One and three eyes at the initial and final postoperative examinations, respectively, had worse vision. Four eyes had the same vision at the initial postoperative examination and one eye had the same vision at the final examination. The mean total follow up for the eyes...
with better and worse vision was 34 and 43 months, respectively. The one eye with the same vision had been followed for 65 months.

The mean latencies and median and mean visual acuities of these patients are graphically summarised in Figure 2. Note that visual acuity measurements before radiation treatment are not available for four of these 12 eyes but were available for all 12 eyes before macular photocoagulation. Visual acuity progressively decreased following radiation treatment until macular photocoagulation was applied at a mean follow-up of 101 months after radiation treatment and 31 and 14 months, respectively, after the first diagnosis of macular oedema and CSRMO.

The total number of CSRMO criteria at the time of the preoperative, initial postoperative, and final postoperative examinations are summarised in Table 1. Six eyes did not have any criteria for CSRMO at the final postoperative examination. Five and six eyes preoperatively had two and three total criteria, respectively; approximately half as many eyes had these total criteria at the final postoperative examination. Also, the percentage of eyes with each criterion decreased following photocoagulation treatment, from 100% for

Figure 3  (A) Preoperative fundus photograph with more than one disc area of retinal thickening which involves the central and inferior macular (CSRMO criteria 1 and 3). Nerve fibre layer infarcts are present but hard exudates are absent (CSRMO criterion 2 is not present). (B) Preoperative fluorescein angiogram (late phase) demonstrates leakage of dye, capillary non-perfusion, and staining of vessel walls. (C) Fundus photograph immediately after treatment shows limited scatter photocoagulation burns. (D) Final postoperative fundus photograph shows photocoagulation scars and decreased nerve fibre layer infarcts. CSRMO criteria 1 and 3 are no longer present (compared with (A)). The media haze is due to two confounding factors (extensive haemorrhage and posterior subcapsular cataract). (E) Final postoperative fluorescein angiogram showing hyper- and hypofluorescence of the photocoagulation scars, decreased leakage of dye, and absence of vascular wall staining (compared with (B)).
Photocoagulation treatment for clinically significant radiation macular oedema

Table 1  Clinically significant radiation macular oedema

<table>
<thead>
<tr>
<th>Total criteria</th>
<th>Preoperative</th>
<th>Postoperative</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Initial</td>
<td>Final</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>2 (17)</td>
</tr>
<tr>
<td>1</td>
<td>1 (8)</td>
<td>1 (8)</td>
</tr>
<tr>
<td>2</td>
<td>2 (42)</td>
<td>6 (50)</td>
</tr>
<tr>
<td>3</td>
<td>3 (50)</td>
<td>3 (25)</td>
</tr>
</tbody>
</table>

Table 2  Confounding factors

<table>
<thead>
<tr>
<th>Factor (number of eyes affected)</th>
<th>Better</th>
<th>Same</th>
<th>Worse</th>
</tr>
</thead>
<tbody>
<tr>
<td>Macular ischaemia (12)</td>
<td>8 (67)</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Optic neuropathy (7)</td>
<td>3 (43)</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Retinal photocoagulation (6)</td>
<td>2 (33)</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Vitreous haemorrhage (2)</td>
<td>1 (50)</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Cataract (2)</td>
<td>1 (50)</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Repaired traction macular detach</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>

Table 3  Summary of study data (12 eyes)

<table>
<thead>
<tr>
<th>Case</th>
<th>Preoperative</th>
<th>Initial postoperative</th>
<th>Final postoperative</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Visual acuity</td>
<td>Follow up (months)</td>
<td>Visual acuity</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>R 20/200</td>
<td>5</td>
<td>20/50</td>
</tr>
<tr>
<td>2</td>
<td>R 20/40</td>
<td>5</td>
<td>20/30</td>
</tr>
<tr>
<td>3</td>
<td>L 20/60</td>
<td>4</td>
<td>20/50</td>
</tr>
<tr>
<td>4</td>
<td>R 20/80</td>
<td>3</td>
<td>20/80</td>
</tr>
<tr>
<td>5</td>
<td>R 20/50</td>
<td>5</td>
<td>20/40</td>
</tr>
<tr>
<td>6</td>
<td>R 20/40</td>
<td>5</td>
<td>20/20</td>
</tr>
<tr>
<td>7</td>
<td>L 20/100</td>
<td>3</td>
<td>20/100</td>
</tr>
<tr>
<td>8</td>
<td>R 20/40</td>
<td>7</td>
<td>20/20</td>
</tr>
</tbody>
</table>

Criteria are defined in Methods section. Confounders: MI=macular ischaemia; ON=optic neuropathy; PRP=panretinal photocoagulation; CAT=cataract; RTMD=repaired traction macular detachment; VH=vitreous haemorrhage.

Discussion

Vision loss as a complication of radiation treatment designed to preserve vision is particularly undesirable. If radiotherapy complications cannot be prevented, it behaves physicians to find efficacious means for treating the complications. We believe these long term visual acuity and anatomical results of photocoagulation for CSRMO suggest that laser treatment is beneficial and not harmful for this sight threatening complication. We agree with others that spontaneous improvement in radiation macular oedema is unlikely to occur, and the experience of other investigators also indicates that photocoagulation treatment of radiation macular oedema is beneficial. The effectiveness of photocoagulation, however, will remain uncertain until a controlled, randomised treatment trial is conducted. This study provides useful pilot data for design of such a trial.

The visual and anatomical results in our patients may have been better if the patients had been treated earlier in their disease process. The diagnosis of CSRMO was not made until an average of over 7 years after the diagnosis of radiation retinopathy. More than a year elapsed, on average, before the CSRMO was photocoagulated. It is likely that photocoagulation treatment, as is the case with diabetic macular oedema, is more effective in preventing vision loss than improving vision already lost due to radiation macular oedema.

Three eyes (cases 2, 5, and 8) had good visual acuity (20/20 to 20/40) at the final postoperative examination, and these three also had the best preoperative visual acuity (20/40 to 20/50) of the 12 study eyes (Table 3).

The hallmark clinical finding of radiation retinopathy is the widespread capillary non-perfusion demonstrated with fluorescein angiography. The resultant macular ischaemia (defined as capillary dropout around the fovea) seen in all 12 of our study eyes supports present knowledge that the primary pathology in radiation retinopathy is damage to vascular endothelial cells. Capillary non-perfusion also occurs in diabetic retinopathy but usually not so extensively as seen in radiation retinopathy.

The more extensive capillary non-perfusion in radiation retinopathy may decrease the beneficial effect of photocoagulation treatment for radiation macular oedema, but the extent of capillary non-perfusion necessary to eliminate any possible beneficial effect is not known.
for either diabetic or radiation macular oedema.

Another significant difference between radiation and diabetic retinopathies may be more extensive damage to ciliary and perhaps choroidal vessels (chorioretinopathy) as well as the retinal pigment epithelium following radiation.10-12 The massive exudates seen preoperatively in the centre of the macula in two of our study eyes (cases 1L and 6R) may be the result of severely compromised transport functions of the retinal pigment epithelium due to radiation damage. Both of these eyes had poor vision pre- and postoperatively.

Optic neuropathy more frequently accompanies the diagnosis of radiation retinopathy than diabetic retinopathy. The vessels supplying the optic nerve are probably not as frequently affected by diabetes mellitus as by irradiation.11 We believe the pre- and postoperative visual acuities of six of our seven study eyes with optic neuropathy would have been better if the optic nerves had not been adversely affected by the radiation. The other eye (case 2) had 20/20 visual acuity postoperatively. The improved vision at the final postoperative examination in this eye and two other eyes (right eye of cases 1 and 6) with optic neuropathy is probably not due to
Photocoagulation treatment for clinically significant radiation macular oedema

spontaneous improvement in vision loss secondary to optic neuropathy, as has been reported,\textsuperscript{13} since the optic neuropathy was diagnosed years before the photocoagulation for CSRMO.

The visual results may have been affected by the panretinal photocoagulation in six study eyes since decreased visual acuity is a known complication of panretinal photocoagulation in eyes with diabetic retinopathy.\textsuperscript{14} Except for the eye with a repaired traction macular detachment, these six eyes had the least chance of having improved vision following macular photocoagulation. The indications for panretinal photocoagulation in these eyes (neovascularisation with preretinal or vitreous haemorrhage designated as radiation retinopathy at high risk for severe vision loss)\textsuperscript{4} suggest that these eyes were more severely affected by the radiation treatment than the eyes not developing these high risk characteristics. The importance of routine, periodic follow up of all patients with radiation retinopathy is emphasised by the vitreous haemorrhage, resultant opacified media, and hand motion visual acuity which occurred more than 4 years after beginning treatment for CSRMO in the left eye of case 6.

In addition to follow up for development of high risk characteristics, eyes with radiation retinopathy need to be followed for recurrent and persistent CSRMO. Retreatment was offered to our patients if CSRMO was present at any follow up examination and microaneurysms, areas of capillary non-perfusion, or diffuse leakage were identified which could be responsible for the CSRMO. This need for follow up and retreatment, if necessary, is similar to eyes with clinically significant diabetic macular oedema.\textsuperscript{15}

In addition to the visual acuity results, we believe the anatomical results also support a beneficial effect of photocoagulation for CSRMO. The anatomical improvement in eight of these 12 eyes, as judged by a decreased number of CSRMO criteria, suggests the treatment techniques used in this study were successful in decreasing the retinal oedema. Not all treated eyes, however, respond as judged by absence or decreased number of CSRMO criteria following treatment. Comparable anatomical results of macular photocoagulation in diabetic eyes are not available for comparison with our data.

In summary, macular photocoagulation for CSRMO shows promise for decreasing vision loss as well as improving vision already lost due to radiation macular oedema. Presently untreatable associated causes for decreased vision (for example, severe macular ischaemia, radiation optic neuropathy, and perhaps choroidopathy with retinal pigment epithelial atrophy) in some patients with CSRMO may prevent or lessen functional improvement (better vision) even though anatomical improvement (decreased oedema) is achieved with macular photocoagulation.


Supported in part by NIH Grant EY01730, the Charles Foundation (Longwood, FL), and an award from Research to Prevent Blindness, Inc (New York).


Photocoagulation treatment for clinically significant radiation macular oedema.

J L Kinyoun, R W Zamber, B S Lawrence, W E Barlow and A M Arnold

*Br J Ophthalmol* 1995 79: 144-149
doi: 10.1136/bjo.79.2.144

Updated information and services can be found at:
http://bjo.bmj.com/content/79/2/144

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/